CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 50 enrolled
Drug / intervention
pramipexoledrug
Likely dose
pramipexole 0.125 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00597896
NCT00597896Phase 4Completed
CompareCT.gov

Cognitive Enhancement in Bipolar Disorder

Northwell Health·interventional·Posted Jan 18, 2008·Updated Jun 12, 2015

In Brief

A Phase 4 clinical trial evaluating pramipexole for Bipolar Disorder. Completed, enrolled 50 participants across 1 site.

Detailed Summary

The purpose of this study is to examine whether the medication pramipexole (Mirapex) may be able to improve cognitive problems (i.e. difficulties with thinking, memory, and concentration) that may be associated with bipolar disorder.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBipolar Disorder
CountriesUnited States
CollaboratorsStanley Medical Research Institute

Timeline

Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 18, 2008
Enrollment StartOct 1, 2005
Primary CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 18.5 years ago

Interventions

pramipexoledrug

po pramipexole versus matching placebo minimum 0.125 mg bid and maximum 0.75 mg bid